GH Research Plc (GHRS)

Evaluation: Based on all recent filings, financial statements, and news.

See full evaluation
Ask a question about GH Research Plc (GHRS)
Company Performance

Current Price

as of Oct 16, 2024

$7.74

P/E Ratio

N/A

Market Cap

$402.7M

Description

GH Research Plc operates as a holding company, which engages in the provision of biopharmaceutical products and services. It develops therapeutic products for patients of psychiatric and neurological disorders. The firm develops novel and proprietary 5-Methoxy-N and N-Dimethyltryptamine, or 5-MeO-DMT, therapies. The company was founded by Theis Terwey, Florian Schönharting, and Magnus Halle in 2018 and is headquartered in Dublin, Ireland.

Metrics

Overview

  • HQDublin, DU
  • SectorHealth Technology
  • IndustryPharmaceuticals: Major
  • TickerGHRS
  • Price$7.74+9.01%

Trading Information

  • Market Cap$402.70M
  • Float58.51%
  • Average Daily Volume (1m)66,552
  • Average Daily Volume (3m)43,904
  • EPS-$0.67

Company

  • RevenueN/A
  • Rev Growth (1yr)N/A
  • Net Income-$10.38M
  • Gross MarginN/A
  • EBITDA MarginN/A
  • EBITDA-$13.14M
  • EV$456.09M
  • EV/RevenueN/A
  • P/EN/A
  • P/SN/A
  • P/B2.03
Documents